This retrospective chart review of patients less than 18 years old with pulmonary arterial hypertension (PAH) receiving selexipag was conducted to describe selexipag dosing practices, impact on concomitant PAH therapies, and the safety and efficacy of selexipag. Twenty-seven patients aged 1-17 years started a median dose of oral selexipag 100 µg twice daily. Therapy was increased by a median of 100 µg twice daily every 6 days to a maximally tolerated median dose of 800 µg twice daily. All 24 patients on another prostacyclin derivative were able to discontinue therapy at their maximum tolerated selexipag dose; other concomitant PAH therapies did not change. Changes in echocardiogram data and 6-MWT results were variable. No patients discontinued selexipag; four patients received decreased doses due to flushing (n = 1), drug interactions (n = 2), or increased frequency of nose bleeds (n = 1).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00246-024-03513-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review.
Ther Clin Risk Manag
January 2025
Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
Pulmonary arterial hypertension (PAH) is a rare and potentially fatal condition characterized by progressive increases in blood pressure in the arteries of the lungs. Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and endothelial cells to improve blood flow through the lungs and reduce pulmonary vascular resistance. Oral selexipag is effective, but may be discontinued due to factors like side effects, emergency conditions, or inability to take oral medication, potentially leading to severe adverse events, such as rebound pulmonary hypertension and right heart failure.
View Article and Find Full Text PDFSafety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients - An Open-Label Phase 2 Study.
Circ J
January 2025
Department of Echo-imaging Center, Aizawa Hospital.
Background: Selexipag, an oral prostacyclin (PGI) receptor agonist, is approved for adult patients with pulmonary arterial hypertension (PAH). This study evaluated the efficacy and safety of selexipag for Japanese pediatric patients with PAH.
Methods And Results: The study enrolled 6 patients who received selexipag twice daily at an individualized dose based on body weight; maintenance doses were determined for each patient by 12 weeks after starting administration.
Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension.
CPT Pharmacometrics Syst Pharmacol
December 2024
Department of Clinical Pharmacology & Pharmacometrics, Janssen-Cilag S.p.A., Milan, Italy.
Article Synopsis
- Selexipag is an oral medication used to treat pulmonary arterial hypertension (PAH) in adults, but there are currently no approved treatments targeting this pathway for children.
- The researchers aimed to establish appropriate dosing for pediatric patients by using a pharmacokinetic model derived from adult data, creating weight-based dosing groups with specific starting and maximum doses for different age brackets.
- A clinical study involving 63 pediatric PAH patients showed that the adjusted doses for children resulted in similar drug exposure levels to the adult population, confirming the dosing regimen's safety and efficacy for kids aged 2 to under 18.
Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension.
Pulm Circ
July 2024
Janssen Scientific Affairs, LLC Titusville New Jersey USA.
Selexipag is an oral selective agonist of the prostacyclin receptor approved to treat adults with pulmonary arterial hypertension (PAH). Selexipag is initiated at a dose of 200 μg twice daily (bid) and usually titrated up by 200 μg bid weekly (per label) or more slowly (e.g.
View Article and Find Full Text PDFSafety and Effectiveness of Selexipag in Pediatric Pulmonary Hypertension: A Retrospective Multicenter Cohort Study.
J Pediatr
December 2024
Section of Cardiology, Department of Pediatrics, Columbia University Irving Medical Center, Morgan Stanley Childrens Hospital of New York Presbyterian Hospital, New York, NY.
Article Synopsis
- This study investigates the real-world safety and effectiveness of selexipag in treating pediatric patients with pulmonary arterial hypertension (PAH).
- Researchers analyzed data from 87 children, tracking clinical outcomes before and after starting selexipag over various time periods.
- Results show that while add-on therapy improved some hemodynamic parameters early on, transition patients remained stable initially but faced potential functional decline later, indicating the need for continuous monitoring of these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!